Novavax (NVAX) Non-Current Deffered Revenue (2010 - 2026)

Novavax's Non-Current Deffered Revenue history runs 17 years deep, the most recent figure standing at $359.3 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 12.28% year-over-year to $359.3 million; the TTM figure through Mar 2026 stood at $359.3 million (down 12.28% YoY), while the FY2025 annual figure was $358.9 million, down 19.67% from the prior year.
• Non-Current Deffered Revenue was $359.3 million for Q1 2026 at Novavax, roughly flat from $358.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $1.0 billion in Q3 2022 to a low of $179.4 million in Q4 2022.
• Historically, Non-Current Deffered Revenue has averaged $520.3 million across 5 years, with a median of $446.8 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deffered Revenue surged 246.83% in 2023, then plunged 51.33% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $179.4 million in 2022, then soared by 246.83% to $622.2 million in 2023, then fell by 28.19% to $446.8 million in 2024, then dropped by 19.67% to $358.9 million in 2025, then advanced by 0.09% to $359.3 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $359.3 million (Q1 2026), $358.9 million (Q4 2025), and $397.1 million (Q3 2025), per Business Quant data.